Xact Kapitalforvaltning AB bought a new position in shares of Nu Skin Enterprises (NYSE:NUS) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 5,116 shares of the company’s stock, valued at approximately $349,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. Wolverine Asset Management LLC grew its holdings in Nu Skin Enterprises by 106.9% during the 4th quarter. Wolverine Asset Management LLC now owns 1,514 shares of the company’s stock worth $103,000 after acquiring an additional 23,378 shares during the last quarter. Cerebellum GP LLC bought a new stake in shares of Nu Skin Enterprises in the 4th quarter valued at $124,000. Amundi Pioneer Asset Management Inc. bought a new stake in shares of Nu Skin Enterprises in the 4th quarter valued at $192,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Nu Skin Enterprises by 38.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,082 shares of the company’s stock valued at $210,000 after purchasing an additional 858 shares during the last quarter. Finally, Franklin Resources Inc. bought a new stake in shares of Nu Skin Enterprises in the 4th quarter valued at $215,000. 76.48% of the stock is currently owned by hedge funds and other institutional investors.
NYSE:NUS opened at $73.10 on Monday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.17 and a current ratio of 1.74. Nu Skin Enterprises has a 52 week low of $52.88 and a 52 week high of $75.82. The firm has a market capitalization of $3,856.02, a PE ratio of 22.63, a PEG ratio of 2.03 and a beta of 1.36.
The business also recently announced a quarterly dividend, which was paid on Wednesday, March 14th. Investors of record on Monday, February 26th were given a dividend of $0.365 per share. This represents a $1.46 dividend on an annualized basis and a dividend yield of 2.00%. The ex-dividend date was Friday, February 23rd. This is an increase from Nu Skin Enterprises’s previous quarterly dividend of $0.36. Nu Skin Enterprises’s payout ratio is presently 45.20%.
In related news, Chairman Steven Lund sold 81,000 shares of the business’s stock in a transaction on Wednesday, April 4th. The shares were sold at an average price of $75.00, for a total transaction of $6,075,000.00. Following the transaction, the chairman now owns 4,769 shares in the company, valued at approximately $357,675. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Pisano R. Thomas sold 15,000 shares of the business’s stock in a transaction on Wednesday, March 7th. The shares were sold at an average price of $72.00, for a total transaction of $1,080,000.00. Following the transaction, the director now owns 47,437 shares in the company, valued at approximately $3,415,464. The disclosure for this sale can be found here. Insiders have sold a total of 141,843 shares of company stock worth $10,393,337 in the last quarter. 5.20% of the stock is owned by corporate insiders.
A number of research firms have recently commented on NUS. Pivotal Research reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Nu Skin Enterprises in a research note on Friday, February 16th. ValuEngine raised shares of Nu Skin Enterprises from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 2nd. Zacks Investment Research lowered shares of Nu Skin Enterprises from a “hold” rating to a “sell” rating in a research note on Wednesday, December 20th. Stifel Nicolaus upped their price objective on shares of Nu Skin Enterprises from $50.00 to $57.00 and gave the company a “sell” rating in a research note on Friday, February 16th. Finally, Citigroup reaffirmed a “buy” rating and issued a $81.00 price objective (up from $70.00) on shares of Nu Skin Enterprises in a research note on Tuesday, January 23rd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $71.29.
About Nu Skin Enterprises
Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products.
Want to see what other hedge funds are holding NUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nu Skin Enterprises (NYSE:NUS).
Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.
